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a b s t r a c t
Memory dysfunction associated with aging, neurodegenerative and psychiatric disorders represents an
increasing medical need. Advances in research exploring the biological mechanisms underlying learning
and memory have opened new potential approaches for development of memory-enhancing therapies
addressed to selective neuronal targets. In this work, we synthesized some derivatives with a pyrazol-
o[5,1-c][1,2,4]benzotriazine core to identify ligands on GABAA receptors subtype (benzodiazepine site
on GABAA-receptor) endowed with the potential of enhancing cognition activity without the side effects
usually associated with non-selective GABAA modulators. In fact, there is much evidence that GABAA-R
(c-aminobutyric acid, type A receptor) subtype ligands have relevance in learning and memory. In vitro
and in vivo tests have been performed. Pharmacological data indicate that compounds 7, 13, 14 and 22
act as dual functional modulators of GABAA-Rs (promnemonic and anxiolytic agents) while only com-
pounds 3 and 10 stand out as selectively displaying good antiamnesic and procognitive activity (1 and
3 mg/kg, respectively).
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Cognitive dysfunction is one of the most debilitating symptoms
of various acute or chronic neurological disorders. It may be a pro-
dromal phase of Alzheimer’s disease (AD)1–3 as well as a cardinal
feature in psychiatric conditions.4–6 Patients with Parkinson’s dis-
ease7,8 and Down syndrome9 also show alterations in learning
and memory. Since it is widely demonstrated that various neuro-
transmitters are involved in the considered diseases, multiple drug
therapy could be required. The ever-increasing elderly population
and resulting age-related neurological disorders have focused the
attention of the pharmaceutical industry on mild cognitive impair-
ments (MCI) which significantly affect the quality of life.
In the last decade a large amount of evidence suggests that the
c-aminobutyric acid type A receptor (GABAA-R) could be a useful
target for memory enhancement.10,11 It is known that c-aminobu-
tyric acid (GABA) is the major inhibitory neurotransmitter in the
mammalian central nervous system (CNS), acting through ionotro-
pic GABAA-Rs12 and metabotropic (G-protein coupled) GABAB
receptors (GABAB-Rs).
GABAA-Rs, which are members of the ligand-gated ion channels
(LGICs) superfamily, are membrane-bound heteropentameric pro-
teins composed principally of a, b and c subunits. At this time 21
subunits of the GABAA-Rs have been cloned13 and the most com-
mon are two single alpha subunits, two single beta subunits and
one gamma subunit (a)2(b)2c.14 The combination of the isoforms
a1–3,5, b2/3 and c2 form a subset of GABAA-Rs (a1b2c2,
a2b3c2, a3b3c2, a5b3c2) modulated by benzodiazepines (Bzs)
and by ligands (also named non-benzodiazepine ligands) belong-
ing to several chemical classes. The Bz binding site is located at
the interface of an a and a c subunit and its pharmacology is
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http://dx.doi.org/10.1016/j.bmc.2013.02.027
Abbreviations: a7nACh-R, a7nicotinic acetylcoline receptor; AD, Alzheimer’s
disease; BMS, borane methylsulfide; Bz site/GABAA-R, benzodiazepine site on
GABAA receptor; CMC, carboxymethylcellulose; CNS, central nervous system; DAZ,
diazepam, 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one; Flu, flu-
mazenil (Ro15-1788); GABA, c-aminobutyric acid; GABAA-R, c-aminobutyric acid
type A receptor; LGCIs, ligand-gated ion channels; MCI, mild cognitive impair-
ments; PTZ, pentylenetetrazole; SAR, structure affinity relationships.
⇑ Corresponding author. Tel.: +39 0554573766; fax: +39 0554573671.
E-mail address: gabriella.guerrini@unifi.it (G. Guerrini).
Bioorganic & Medicinal Chemistry 21 (2013) 2186–2198
Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmc
Author's personal copy
mainly determined by the alpha isoform.15–18 Genetic and
pharmacological approaches have identified the function of
GABAA-R subtypes. Receptors containing a1b2c2 subunits mediate
sedative, anterograde amnesic and anticonvulsant actions of
diazepam.19–21 The anxiolytic-like effect and muscle relaxant
activities are mediated by the a2bc2 and a3bc2 receptors; the
a3-containing GABAA-Rs may be involved in the inhibitory input
for the dopaminergic system22–24 and the a5bc2 receptors may
influence learning and memory processes.18–25 The important role
of the a5bc2 GABAA-Rs, mainly localized in the hippocampus26,27
which is involved in cognitive functions, has been widely studied.
The GABAA a5 receptors’ density and function remain relatively
intact28,29 in the learning impairment in Alzheimer’s disease while
changes in many neurotransmitter receptors and overall choliner-
gic neurons are depleted during the disease. Several studies10,30
suggest that an a5-subtype selective inverse agonist could be pro-
cognitive without inducing convulsions and/or anxiety and many
different chemical classes endowed with selective affinity or selec-
tive efficacy have been identified.31–33 Compounds containing the
triazolopyridazine,34 the triazolophthalazine35 and the pyrazolotri-
azine30 core showed either high affinity or high inverse efficacy at
the a5 subtype. During evolution of the triazolophthalazine
ligands, several bicyclic36,37 and tricyclic compounds were synthe-
sized38 and among them, the ligands a5IA, a5IA-II and MRK-016
emerged.10,39,40
Our research group has been extensively involved in the design
of derivatives containing a pyrazolo[5,1-c][1,2,4]benzotriazine
system, with the aim of identifying ligands which bind to the Bz
site on the GABAA-R with high affinity and selective pharmacolog-
ical activity as anxiolytic-like agents or promnemonic agents. In
our recent study the 3-iodo-8-(pyridin-4-ylmethoxy)pyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide 1,41 emerges as the compound
that improves mouse memory processes selectively, safely, in a
statistically significant manner, and in strict chemical relationship
to a5IA, a5IA-II and MRK-016 (Chart 1).
In the present study, lead compound 1 was optimized mainly
through classical isosteric replacement at position 8 or through
the introduction of 5-membered heterocycles (as triazole, or oxadi-
azole) in position 3. The binding affinities of the new compounds
were investigated and for preliminary pharmacological studies,
six compounds among the most representative (bearing different
chemical groups) were evaluated in vivo.
2. Chemistry
All new pyrazolo[5,1-c][1,2,4]benzotriazine derivatives 2–6, 8,
10–25 here described are listed in Table 1 (chemical data). The
new 3-iodo-8-heteroarylmethylamino derivatives 2–5 were pre-
pared from compound I 3-iodo-8-chloropyrazolo[5,1-c][1,2,4]ben-
zotriazine 5-oxide42 treated with an excess of suitable
heteroarylalkylamine. The 3-iodo-8-(pyridin-4-ylmethoxy)pyraz-
olo[5,1-c][1,2,4]benzotriazine 5-oxide,41 our lead compound in this
work (1), was used as starting material for the synthesis of new
compound 6, its N-oxide derivative on the pyridine ring useful
for SAR (Scheme 1).
Compound II (3-carboxy-8-chloropyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide43) was used as starting material to obtain the
3-methyl-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine derivative 8
(Scheme 2) using borane dimethylsulfide complex as reducing
agent.
This borane complex is reported to reduce the carboxy group to
methyl group.44 Compound 8was then oxidized to the correspond-
ing N5-oxide 9, already reported in our previous work, but synthe-
sized with a more complex method and with minor yields.45 The
nucleophilic substitution on compound 9 with 4-pyridylmethanol,
2-chloro-4-hydroxymethylpyridine, and (2-(hydroxymethyl)furan)
was realized by phase transfer catalysis (PTC),41 and the com-
pounds 10–12 were, respectively obtained (Scheme 2).
The compounds bearing the oxadiazole or the triazole ring at
position 3 of the pyrazolobenzotriazine system were prepared
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according to two synthetic pathways (Scheme 3A and B), depend-
ing on the yields or the best reaction work-up for the obtaining of
the desired compounds.
To synthesize the derivatives 13–15 (route A), the first step was
to transform the 3-amide group of compound III, 3-carboxamido-
8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide,43 into the
dimethylaminovinyl derivative IV.46 Then the next cyclization with
NH2OHHCl gave the corresponding 3-(1,2,4-oxadiazol-3-methyl-
5-yl) derivative V.46 In turn, this compound represented the start-
ing material for the nucleophilic substitution of the 8-chlorine
atom by PTC. The suitable alcohol is added to a two-phase system
(strong aqueous sodium hydroxide solution (40%) and methylene
chloride with tetrabutylammonium bromide (NBu4+Br) as cata-
lyst) and compounds 13–15 were obtained.
To obtain the 3-(1,2,4-triazol)-3-yl derivatives, we used route B
(Scheme 3), in which the nucleophilic substitution of 8-chlorine on
Table 1
Chemical data for new synthesized compounds
N
N
+
N
N
R8
O
-
R3
No. R3 R8 Yield (%) Mp (C) (recryst. solvent)
1a I OCH2-4-Py —
2 I NHCH2-4-Py 25 220–222 (Ethanol)
3 I NHCH2-3-Py 20 230 dec (Ethanol)
4 I NHCH2-2-Py 19 205 dec (Ethanol)
5 I NHCH2-2-furyl 75 210–211 (Ethanol)
6 I OCH2-4-Py-N-oxide 60 236–237 (Methoxyethanol)
7a I OCH2-2-thienyl —
8 Me Cl 60 156–157 (Ethanol)
9b Me Cl 23 —
10 Me OCH2-4-Py 50 241–242 (Methoxyethanol)
11 Me OCH2-2-Cl-pyridin-4-yl 25 276 dec (Ethanol)
12 Me OCH2-2-furyl 50 296–297 (Ethanol)
13 1,2,4-Oxadiazol-3-Me-5-yl OCH2Ph 79 240–241 (Isopropyl alcohol)
14 1,2,4-Oxadiazol-3-Me-5-yl OCH2-4-Py 89 223–224 (Methoxyethanol)
15 1,2,4-Oxadiazol-3-Me-5-yl OCH2-2-thienyl 87 240 dec (Methoxyethanol)
16 CONH2 OCH2Ph 78 239–240 (Methoxyethanol)
17 CONH2 OCH2-4Py 80 240–241 (Methoxyethanol)
18 CONH2 OCH2-2-thienyl 87 229–230 (Methoxyethanol)
19 CO–N@CH –N(Me)2 OCH2Ph 80 209–210 (Toluene)
20 CO–N@CH –N(Me)2 OCH2-4-Py 88 250–251 (Toluene)
21 CO–N@CH –N(Me)2 OCH2-2-thienyl 72 235–236 (Toluene)
22 1,2,4-Triazol-3-yl OCH2Ph 95 259–260 (Methoxyethanol)
23 1,2,4-Triazol-3-yl OCH2-4-Py 80 269–270 (Methoxyethanol)
24 1-Me-1H-1,2,4-triazol-5-yl OCH2Ph 80 235–236 (Methoxyethanol)
25 1-Me-1H-1,2,4-triazol-3-yl OCH2Ph 70 255 dec (Ethanol)
a See Ref. 41.
b See Ref. 45.
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compound III43 was the first step of synthesis and compounds 16–
18 were obtained. Then the treatment of 16–18 with dimethyl-
formamide–dimethylacetal (DMF–DMA) gave the corresponding
acylamidines 19–21, key intermediates for the synthesis of 3-tria-
zole derivatives. Only intermediates 19 and 20 cyclized with
hydrazine hydrate at 90 C, gave the corresponding 22 and 23,
while the desired derivative was not obtained from compound
21 even by modifying the reaction conditions.
To better elaborate the structure affinity relationships (SAR), we
decided to methylate the 1,2,4-triazole ring of compound 22 with
MeI. Street38 and Del Giudice47 reported that with NaH as alkaline
medium the two regioisomers N1 and N2 were prevalently ob-
tained, while the N4 methylation was not very easy to realize in
these conditions.48,49
In our synthetic procedure (NaH/DMF/MeI), as expected, amixture
of two isomers in a ratio of about 3/1 (assigned byNCH3 peaks at 4.051
and 4.153 ppm in 1H NMR spectroscopy) was recovered and only one
was obtained as pure product (isomer with the NCH3 signal at
4.051 ppm) by crystallization. Unfortunately, an X-ray analysis was
not performed because unsuitable crystals were obtained and it was
impossible to assign the isomer structure using only 1HNMR spectros-
copy. Thus, to determine exactly which isomer was obtained, a differ-
ent synthetic approach anddifferent reaction conditionswereused. By
reaction of 19 with methylhydrazine (Scheme 4) we obtained only
the isomer 3-(1,2,4-triazol-1-methyl-5-yl)-8-benzyloxypyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide 24 whose structure was deter-
mined by crystallographic data (Fig. 1). Since the NCH3 peak of 24 falls
at 4.153 ppm, compound 24 is not the same isomer obtained by crys-
tallization in the previous reaction. Thus, obviously, we can assign to
this latter compound the structure of 3-(1,2,4-triazol-1-methyl-3-yl)-
8-benzyloxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide 25. However,
to try to synthesize unambiguously the isomer 25 a literature proce-
dure48 was followed choosing lithium hydroxide as alkaline medium.
Thus 22was alkylated with MeI in LiOH and only the regioisomer 25
was obtained.
3. Result and discussion
3.1. In vitro binding
The Bz site/GABAA-R binding affinity of newly synthesized com-
pounds was evaluated by their ability to displace [3H]flumazenil
(Ro15-1788) from its specific binding in bovine brain membrane
and was expressed as Ki value only for those compounds inhibiting
radioligand binding by more than 80% at fixed concentrations of
10 lM.
The binding data (Table 2) show that most of the new synthe-
sized compounds have receptor recognition (except 24 and 25)
and that some compounds (2–5) were able to bind to Bz site/GA-
BAA-R with affinity value (Ki) in a range of 0.2–0.7 nM.
The isosteric substitution O/NH, at 8-position in the lead com-
pound 1, afforded compound 2 endowed with an excellent affinity
value (2 Ki = 0.331 vs 1, Ki = 1.3 nM), maintained also in isomeric
compounds 3 and 4, the 3- and 2-pyridil derivatives, (Ki = 0.332
and 0.717 nM, respectively). The substitution of the pyridine ring
in compound 4 with a furyl ring gives compound 5 with Ki va-
lue = 0.23 nM showing that the introduction of a 5-membered het-
erocycle is again positive. On the basis of binding data, we observe
that compounds 2–5 show the best affinity values, confirming pre-
viously reported data45 for the arylalkylamino derivatives. In fact,
at position 8, the NH moiety (hydrogen bond donor) versus O
(hydrogen bond acceptor) plays a key role in receptor recognition,
engaging a hydrogen bond interaction stronger than the oxygen
atom (data not reported).
Compound 6, the N-oxide derivative of the lead compound,
shows an affinity value reduced fourteen times (Ki = 20.4 nM) with
respect to 1, whereas when the pyridine ring was substituted with
a thienyl ring, as in compound 7, comparable affinity value was
maintained (Ki = 1.2 nM).
The substitution on lead compound 1 of the iodine atom with
a methyl group gave compound 10 with affinity binding 24-fold
lower (10 Ki = 24.1 nM vs 1 Ki = 1.3 nM), while its 2-chloroderiva-
tive 11 has a good affinity value (Ki = 7.4 nM). The substitution of
the pyridine ring with a furan moiety gave comparable affinity
value to 10 (Ki = 30.9 nM). Despite the reduced ability of the
methyl group to form a lipophilic interaction with a receptor,
(methyl, p = 0.56 and iodine p = 1.12)50 the introduction of the
heteroaromatic ring at position 8 gave a good hydro/lipophilic
balance.
The substitution of iodine, at position 3 in the lead compound,
with different 5-membered heterocycles, produced compounds
13–15 and 22–23 with Ki values in a range of 70.7–1623 nM. The
methylation of compound 22 gave the two regioisomers 24 and
25 that are lacking receptor recognition, evidencing the key role
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of triazole NH as hydrogen bond donor or the steric hindrance of
the methyl group.
We also tested the intermediates 16–21 useful for the synthesis
of these latter derivatives and they show affinity in the range of
323–1200 nM. Compound 13 results in being the best ligand with
a Ki value of 70.7 nM.
3.2. In vivo activity
Compounds 3, 7, 10, 13, 14 and 22 were chosen for in vivo tests
in animal models, using various rodent species (mice and rats). The
effects on learning and memory (passive avoidance test and social
learning) and some potential benzodiazepine actions were consid-
ered (anticonvulsant activity, potential anxiolytic-like effects and
the effect on motor coordination).
3.3. Passive avoidance test
Inorder to investigate theeffectof compounds3,7,10,13,14and22
on learning andmemory,mouseperformance in thepassive avoidance
test (anexperiment inwhichtheanimal learns toavoidanoxiousevent
by suppressing a particular behavior) was evaluated.
Examining the results, we can say that the training session la-
tency values did not differ for the various compounds, while the
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retention latencies differed for some products (depending on the
doses). As depicted in Figure 2, mouse performances were tested
with compounds 3 (0.1, 1, 3 and 10 mg/kg po), 7 (1, 10, 30 and
100 mg/kg po), 10 (1, 3 and 10 mg/kg po), 13 (1, 3, 10 and
30 mg/kg po), 14 (3, 10 and 30 mg/kg po), 22 (1, 3 and 10 mg/kg
po). All tested compounds produced no amnesic effect, but im-
proved mouse memory processes by increasing the retention la-
tency compared to control in a statistically significant manner.
The most interesting results were recorded for 3 at 1 mg/kg, for
10 and 22 at 3 mg/kg, and for 13 at 10 mg.
To evaluate the antiamnesic effect of the compounds, (their
capability to prevent the amnesic effect of scopolamine (1.5 mg/
kg)), we tested them at the dose at which they were completely de-
void of promnemonic activity (7, 10, 13 and 22 at 1 mg/kg; 14 at
3 mg/kg and 3 at 0.1 mg/kg) in passive avoidance test with scopol-
amine (Fig. 2). All compounds were able to completely prevent the
amnesic effect of scopolamine.
3.4. Social learning
In the social learning test adult rats were treated with com-
pounds 3 (0.3–10 mg/kg po), 7 (10–100 mg/kg po), 10 (1–
10 mg/kg po), 13, 14, and 22 (10 mg/kg po) and the duration
of exploration of the familiar partner in the second session
was shortened in comparison with carboxymethylcellulose
(CMC)-treated rats; positive control: piracetam (30 mg/kg po
(Table 3). No curtailment was observed if an unknown partner
was presented to adult rats (data not shown). No compound
modified the duration of active exploration in the first session
in comparison with CMC-treated rats. All compounds exhibited
comparable efficacy even if the highest potency was exhibited
by 3 (1 mg/kg) and the lowest by 7 (30 mg/kg). The shortening
of the exploring time of the familiar rat induced by 3, 7, 10,
13, 14 and 22 in the social learning test indicated procognitive
activity in the absence of amnesia.
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3.5. Light–dark box
The effects of compounds 3, 7, 10, 13, 14 and 22 on mouse anx-
iety, compared with diazepam (10 mg/kg po), were studied using a
light/dark box apparatus. All compounds were tested starting from
the lowest dose at which they have procognitive activity: 3 (1 mg/
kg po), 7 (30 mg/kg po), 10 (3 and 10 mg/kg po), 13, 14 and 22 (3,
10 and 30 mg/kg po) (Fig. 3). Compounds 13, 14 and 22 at the
doses of 10 and 30 mg/kg po and 7 at the dose of 30 mg/kg po re-
vealed an anxiolytic effect, comparable to diazepam, in a statisti-
cally significant manner. The anxiolytic effect of compounds was
completely antagonized by flumazenil (at a dose of 100 mg/kg
po), a dose at which flumazenil was able to antagonize the anxio-
lytic effect of diazepam (data not shown). Compounds 3 and 10
showed no activity in this experimental model.
3.6. Rota-rod test
The effects of compounds 3 and 10 (10 mg/kg po), 7, 13, 14 and
22 (30 mg/kg po) were studied in the mouse rota-rod test, in com-
parison with diazepam (10 mg/kg po), in order to determine any
motor incoordination activity. Table 4 reports the pretest and the
falls 15, 30, 45, 60 min after the treatment. None of the considered
compounds induced any effect on the number of mouse falls from
the rota-rod, confirming that mice learned to stay on the rota-rod
since the number of falls decreased in a time-dependent manner.
Protection from convulsions was evaluated in mice using penty-
lentetrazole (PTZ) as chemical convulsant agent. All compounds
were tested at the doses of 10 mg/kg po, except 3 that was tested
at 1 mg/kg po. Diazepam (10 mg/kg po) completely protected
against PTZ-induced shocks and convulsions. These compounds
were devoid of any effect on PTZ-induced shocks and convulsions
(Table 5).
3.7. Interaction with GABAA receptor subtypes
Based on the above pharmacological results, we decided to ver-
ify the interaction of compounds 3 and 10, that show selective ant-
iamnesic and promnemonic activity, with GABAA receptor
subtypes (a1, a2, a5). Compound 3 was able to bind the a1- and
a5-subtype receptors with an affinity value in the nanomolar
range (Ki = 0.449 and 24.9 nM, respectively) and showed a percent
of inhibition (I% = 37) for the a2-subtype receptor. Surprisingly,
compound 10 was able to bind only the a1-subtype receptor
(Ki = 22.7 nM) and had no affinity for a2- and a5-subtype receptors
(Table 6). Binding to the GABAA-R subtype indicated that com-
pound 3 has subtype affinity for a5 that could explain its in vivo
efficacy in memory tasks. Instead, compound 10, despite its activ-
ity in the mouse/rat memory task, has no affinity for the a5-sub-
type and thus involvement of the GABA system is excluded.
Table 2
BZR ligand affinity of new compounds
N
N+
N
N
R8
O-
R3
No. R3 R8 I%a or Kib (nM)
1c I OCH2-4-Py 1.30 ± 0.10
2 I NHCH2-4-Py 0.33 ± 0.08
3 I NHCH2-3-Py 0.33 ± 0.07
4 I NHCH2-2-Py 0.72 ± 0.06
5 I NHCH2-2-furyl 0.23 ± 0.02
6 I OCH2-4-Py-N-oxide 20.4 ± 2.9
7c I OCH2-2-thienyl 1.20 ± 0.10
8 Me Cl 400.0 ± 11.0
9d Me Cl 315.0 ± 20.0
10 Me OCH2-4-Py 24.1 ± 2.0
11 Me OCH2-2-Cl-pyridin-4-yl 7.49 ± 0.19
12 Me O-CH2-2-furyl 30.9 ± 3.0
13 1,2,4-Oxadiazol-3Me-5-yl OCH2Ph 70.7 ± 5.7
14 1,2,4-Oxadiazol-3Me-5-yl OCH2-4-Py 453.2 ± 53.7
15 1,2,4-Oxadiazol-3Me-5-yl OCH2-2-thienyl 1623.0 ± 150.9
16 CONH2 OCH2Ph 323.7 ± 33.0
17 CONH2 OCH2-4-Py 1200.0 ± 118.0
18 CONH2 OCH2-2-thienyl 959.6 ± 77.8
19 CO–N@CH –N(Me)2 OCH2Ph 86.6 ± 13.2
20 CO–N@CH –N(Me)2 OCH2-4-Py 514.8 ± 78.2
21 CO–N@CH –N(Me)2 OCH2-2-thienyl 620.0 ± 54.2
22 1,2,4-Triazol-3-yl OCH2Ph 325.2 ± 30.0
23 1,2,4-Triazol-3-yl OCH2-4-Py 167.9 ± 15.1
24 1-Me-1H-1,2,4-triazol-5-yl OCH2Ph 46%
25 1-Me-1H-1,2,4-triazol-3-yl OCH2Ph 50%
a Percent of inhibition of specific [3H]Ro15-1788 binding at 10 lM concentration
are means ± SEM of five determinations.
b Ki value are means ± SEM of five determinations.
c See Ref. 41.
d See Ref. 45.
Figure 2. Effect of new compounds in Mouse Passive Avoidance test. All drugs were administered po 30 min before training session with the exception of scopolamine that
was injected immediately after punishment. Each value represents the mean of 10–12 mice. The first column represents the training session of CMC-treated group. ^P <0.05
and ⁄P <0.01, versus control mice. §P <0.01 versus scopolamine-treated mice.
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3.8. Effect on ACh release
As a preliminary study, the release of ACh was evaluated and, as
shown in Figure 4, a statistically significant increase of ACh release
in freely moving rats was induced by administration of compound
10 (10 mg/kg ip), which peaked 60–80 min after administration
and returned to basal values within 120 min.
4. Conclusion
A series of new 3,8 disubstituted pyrazolo[5,1-c][1,2,4]benzotri-
azine derivatives were designed and synthesized to identify li-
gands to the Bz site on GABAA-R endowed with high affinity and/
or selective efficacy as promnemonic agents. All new compounds
were studied in in vitro tests and six compounds, with opportune
features in their substituents, were chosen for preliminary in vivo
evaluation of their potential effect on learning, memory and anxi-
ety. The modification (O/NH at position 8 and I/Me at position 3) on
lead compound 1 allowed us to obtain compounds 3 and 10 that
have a selective promnemonic effect at 1 and 3 mg/kg. The selec-
tivity of these two compounds was assessed in recombinant sub-
types GABAA-R (a1b2c2, a2b2c2, a5b3c2.): compound 3 was able
to bind the a1- and a5-subtype receptors with an affinity value
in the nanomolar range (Ki = 0.449 and 24.9 nM, respectively)
and shows an inhibition percent (I% = 37) to a2-subtype receptor.
Compound 10, surprisingly, was able to bind only a1-subtype
receptors (Ki = 22.7 nM) and shows no affinity for a2- and a5-sub-
type receptor. From these biological results, compound 3 has sub-
type affinity for a5 that could explain its in vivo efficacy on
memory tasks. Instead, 10, despite its activity on mouse/rat mem-
ory tasks, has no affinity for a5-subtype and thus another neuro-
transmitter, rather than GABA, could be involved. A preliminary
study showed that 10 enhances the percentage of ACh release
and the maximum effect was reached 60–80 min after the admin-
istration. This aspect will be the object of our next research.
Another important result was obtained for compounds 13, 14
and 22, which possess both promnemonic- and anxiolytic-like ef-
fects in the range of 10–30 mg/kg. Elucidation of this dual profile
could be an attractive research starting point for neurological dys-
functions where both cognitive enhancement and anxiolysis are
required.
5. Experimental section
5.1. Chemistry
Melting points were determined with a Gallenkamp apparatus
and were uncorrected. Silica gel plates (Merk F254) and silica gel
Table 3
Effect of compounds 3, 7, 10, 13, 14, 22 in rat social learning test
Compounds Dose (mg/kg) po First session Second session D
Treatment
CMC 1% 0.1 ml 63.1 ± 6.1 35.3 ± 3.3 27.6
3 0.3 58.3 ± 8.4 28.9 ± 6.1 29.4
1 65.3 ± 3.1 21.6 ± 4.2^ 43.7
10 63.4 ± 7.5 20.9 ± 3.7^ 42.5
7 10 68.3 ± 8.5 35.8 ± 3.2 32.5
30 65.9 ± 7.3 23.6 ± 4.1^ 42.3
100 67.7 ± 6.6 25.8 ± 4.9^ 41.9
10 1 62.7 ± 7.3 29.5 ± 5.5 33.2
3 63.4 ± 5.2 20.2 ± 4.3^ 43.2
10 65.1 ± 7.3 23.7 ± 4.4^ 41.4
13 10 69.8 ± 6.6 26.7 ± 3.8^ 43.1
14 10 66.3 ± 7.7 21.7 ± 3.6^ 44.6
22 10 65.8 ± 7.1 25.5 ± 4.3^ 40.3
Piracetam 30 68.2 ± 7.3 21.9 ± 5.1^ 46.3
^ P <0.05 versus control rats. Tests was performed 30’ after drug administrations.
Each value represents the mean of six rats.
Figure 3. Effect of compounds 3, 7, 10, 13, 14 and 22 in light–dark box test. All drugs were administered po 30 min before the test. Each value represents the mean of eight
mice. First column represents the number of transfer in 5 min, and the second column represents the time spent in light. ⁄P <0.01 versus control mice. §P <0.01 versus
flumazenil-treated mice.
Table 4
Effect of 3, 7, 10, 13, 14, 22 in the mouse rota-rod test
Treatment Falls from rotating rod after treatment
Compounds Dose (mg/kg)
po
Pre-test 15 min 30 min 45 min
CMC 1% 0.1 mL 6.1 ± 0.5 5.5 ± 0.5 3.2 ± 0.4 2.5 ± 0.4
3 10 6.3 ± 0.5 4.9 ± 0.4 3.1 ± 0.3 2.4 ± 0.4
7 30 5.8 ± 0.4 5.1 ± 0.3 3.0 ± 0.2 2.8 ± 0.3
10 10 5.9 ± 0.5 5.2 ± 0.4 3.0 ± 0.4 2.8 ± 0.4
13 30 5.9 ± 0.5 5.4 ± 0.5 3.4 ± 0.3 2.7 ± 0.4
14 30 6.3 ± 0.6 5.3 ± 0.5 3.6 ± 0.4 2.4 ± 0.5
22 30 6.0 ± 0.4 5.3 ± 0.4 3.4 ± 0.4 2.9 ± 0.3
Diazepam 10 6.3 ± 0.3 6.4 ± 0.3^ 6.4 ± 0.5⁄ 5.6 ± 0.4⁄
Each value represents the mean of five mice. ^P <0.05, ⁄P <0.01 in comparison with
CMC treated mice.
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60 (Merk 70–230 mesh) were used for analytical and column chro-
matography, respectively. The structures of all compounds were
supported by their IR spectra (KBr pellets in nujol mulls, Perkin–El-
mer 1420 spectrophotometer) and 1H NMR data (measured with a
Bruker 400 MHz). Chemical shifts were expressed in d ppm, using
DMSO-d6 or CDCl3 as solvent. The chemical and physical data of
new compounds are shown in Table 1; all new compounds possess
a purity P95%: microanalyses were performed with a Perkin–El-
mer 260 analyzer for C, H, N. The crystal structure of compound
25 was solved by means of single-crystal X-ray diffraction.
5.1.1. General procedure for the synthesis of 2–5
To the starting material 3-iodo-8-chloro pyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide I42 (0.150 mmol) in EtOH
(5 mL) was added an excess of suitable amine (2 mL) and was kept
under vigorous stirring at 50 C. TLC monitored the reaction and,
when the starting material disappeared, ice was added to obtain
a precipitate. Compounds 2 and 5 were purified by column chro-
matography (toluene/ethyl acetate 8/2)
5.1.2. 3-Iodo-8-(pyridin-4-ylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (2)
Yellow crystals; TLC eluent: toluene/ethyl acetate 8:2 v/v; IR
m cm1 3271; 1H NMR (DMSO-d6) d 8.54 (d, 2H, H-20 and H-60,
J = 5.5 Hz); 8.37 (m, 1H, NH, exch.); 8.23 (s, 1H, H-2); 8.14 (d,
1H, H-6, J = 8.9 Hz); 7.38 (d, 2H, H-30 and H-50, J = 5.5 Hz); 7.03
(m, 2H, H-7 and H-9); 4.55 (d, 2H, CH2-N, J = 5.2 Hz). Anal. C,
H, N.
5.1.3. 3-Iodo-8-(pyridin-3-ylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (3)
Yellow crystals; TLC eluent: toluene/ethyl acetate 8:2 v/v; IR m
cm1 3270; 1H NMR (DMSO-d6) d 8.67 (s, 1H, H-20); 8.50 (d, 1H,
H-60, J = 4.9 Hz); 8.42 (t, 1H, NH, exch., J = 5.2 Hz); 8.25 (s, 1H, H-
2); 8.15 (d, 1H, H-6, J = 8.9 Hz); 7.80 (d, 1H, H-40, J = 7.8 Hz); 7.40
(dd, 1H, H-50, J = 7.8, 4.9 Hz); 7.05 (m, 2H, H-7 and H-9); 4.60 (d,
2H, CH2-N, J = 5.2 Hz). Anal. C, H, N.
5.1.4. 3-Iodo-8-(pyridin-2-ylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (4)
Yellow crystals; TLC eluent: toluene/ethyl acetate 8:2 v/v; IR m
cm1 3270; 1H NMR (DMSO-d6) d 8.58 (d, 1H, H-60, J = 5.0 Hz);
8.40 (t, 1H, NH, exch., J = 5.3 Hz); 8.23 (s, 1H, H-2); 8.12 (d, 1H,
H-6, J = 8.9 Hz); 7.79 (dt, 1H, H-40, J = 8.0, 2.1 Hz); 7.42 (d, 1H, H-
30, J = 8.0 Hz); 7.32 (dt, 1H, H-50, J = 7.7, 1.2 Hz); 7.06 (m, 2H, H-7
and H-9); 4.65 (d, 2H, CH2-N, J = 5.3 Hz). Anal. C, H, N.
5.1.5. 3-Iodo-8-(fur-2-ylmethylamino)pyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (5)
Yellow crystals; TLC eluent: toluene/ethyl acetate 8:2v/v; IR m
cm1 3272; 1H NMR (DMSO-d6) d 8.28 (s, 1H, H-2); 8.22 (t, 1H,
NH, exch., J = 5.3 Hz); 8.14 (d, 1H, H-6, J = 8.9 Hz); 7.65 (s, 1H, H-
50); 7.18 (d, 1H, H-9, J = 2.7 Hz); 7.03 (dd, 1H, H-7, J = 8.9, 2.7 Hz);
6.43 (m, 2H, H-30 and H-40); 4.55 (d, 2H, CH2-N, J = 5.3 Hz). Anal.
C, H, N.
Table 5
Lack of anticonvulsant activity of 3, 7, 10, 13, 14, 22 in comparison with diazepam in
PTZ treated mice
Compounds Treatment (mg/kg)
po
% Protection on PTZ induced
convulsions
CMC 1% 0.1 mL 7.1
Diazepam 10 100*
3 1 0
7 10 0
10 10 0
13 10 10
14 10 10
22 10 0
Pentylenetetrazole (PTZ) 90 mg kg1 ip. All compounds were administered 30 min
before test. Each value represents the mean of 10 mice.
* P <0.01 versus control mice.
Table 6
Affinity value at recombinant a1,2,5b2c2 GABAA/Bz complex subtypes
No. I%a or Kib (nM)
Cortex a1 a2 (%) a5
3 0.33 ± 0.07 0.45 ± 0.04 37 24.9 ± 2.0
10 24.1 ± 2.0 22.7 ± 2.0 5 36%
a Percent of inhibition of specific [3H]Ro15-1788 binding at 10 lM concentration
are means ± SEM of five determinations.
b Ki value are means ± SEM of five determinations.
Figure 4. Release of ACh of 10. Saline and compound 10 were injected at time ‘0’, ip number of rat (Wistar): 6. ⁄P <0.01 versus saline.
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5.1.6. 3-Iodo-8-(1-oxidopyridin-4-ylmethoxy)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (6)
An aqueous solution of hydrogen peroxide (30%, 3 mL) in acetic
acid (17 mL) was added to 141 (210 mg, 0.5 mmol) and the mixture
was stirred at 90 C for 3 h. The mixture was cooled, and a second
portion of H2O2 (1 mL) was added. The mixture was stirred for an-
other 15 h at 90 C monitoring by TLC (eluent: dichloromethane/
methanol 10:1 v/v). The pH was adjusted to 6 with aqueous solu-
tion of sodium hydroxide (10%). The yellow crude precipitate was
filtered off and was recrystallyzed by methoxyethanol. Orange
crystals; IR m cm1 1538; 1H NMR (DMSO-d6) d 8.40 (d, 1H, H-6,
J = 8.9 Hz); 8.38 (s, 1H, H-2); 8.27 (d, 2H, H-20 and H-60,
J = 5.5 Hz); 7.77 (d, 1H, H-9, J = 2.7 Hz); 7.55 (d, 2H, H-30 and H-
50, J = 5.5 Hz); 7.38 (dd, 1H, H-7, J = 8.9, 2.7 Hz); 5.45 (s, 2H,
CH2O). Anal. C, H, N.
5.1.7. 3-Methyl-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine (8)
To 1 mmol of compound II43 in dry THF (100 mL) a solution of
2.5 mmol borane dimetilsulphide complex (BMS) was added. The
temperature was maintained approximately at 0 during the addi-
tion. The solution was then brought to reflux and maintained there
for 1 h. Then, when the temperature was about 0 C, the reaction
mixture was quenched by the slow addiction of 10 mL of methanol.
HCl conc. was then added slowly (pH 2), refluxed for 1 h and then,
when the temperature was 0 C, sodium hydroxide solution (40%)
were added. The aqueous phase was extracted with ether (three
times with a total of 100 mL). After drying with sodium sulfate, a
precipitate was recovered. Yellow crystals; TLC eluent: toluene/
ethyl acetate 8:2v/v; 1H NMR (CDCl3) d 8.55 (d, 1H, H-6,
J = 8.9 Hz); 8.43 (d, 1H, H-9, J = 2.7 Hz); 8.09 (s, 1H, H-2); 7.67
(dd, 1H, H-7, J = 8.9, 2.7 Hz); 2.70 (s, 3H, CH3). Anal. C, H, N.
5.1.8. 3-Methyl-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-
oxide (9)
To a solution of 8 (0.1 mmol) in acetic acid (30 mL) were added
hydrogen peroxide 30% (6 mL).
The solution was refluxed for 8 h and the precipitate was fil-
tered and recrystallized obtaining the same product reported in
our previously paper.45
Yellow crystals; TLC eluent: isopropyl ether/cyclohexane 8:3 v/
v; 1H NMR (CDCl3) d 8.45 (d, 1H, H-6, J = 8.9 Hz); 8.35 (d, 1H, H-9,
J = 2.7 Hz); 7.90 (s, 1H, H-2); 7.55 (dd, 1H, H-7, J = 8.9, 2.7 Hz); 2.40
(s, 3H, CH3). Anal. C, H, N.
5.1.9. General procedure for the synthesis of 10–18
The reaction was carried out in 10 mL of dichloromethane to
which was added the starting material 9, III,43 V,46 (0.3 mmol),
5 mL of 40% sodium hydroxide solution, 0.5 mmol of tetrabutylam-
monium bromide (PTC), and the suitable alcohol in large excess
(ratio with starting material 1:15) under vigorous stirring. The
reaction was monitored by TLC, and when the starting material
disappeared, the organic layer was separated and the aqueous
layer extracted twice with 10 mL of dichloromethane. The com-
bined organic extracts were evaporated and the residue was recov-
ered with isopropil ether and then recrystallized by suitable
solvent.
5.1.10. 3-Methyl-8-(pyridin-4-ylmethyloxy)pyrazolo[5,1-c]
[1,2,4]benzotriazine 5-oxide (10)
From 9 yellow crystals; TLC eluent: dichloromethane/methanol
10:1 v/v; 1H NMR (DMSO-d6) d 8.62 (d, 2H, H-20 and H-60,
J = 5.5 Hz)); 8.38 (d, 1H, H-6, J = 8.9 Hz); 8.14 (s, 1H, H-2); 7.74
(d, 1H, H-9, J = 2.7 Hz); 7.52 (d, 2H, H-30 and H-50, J = 5.5 Hz);
7.36 (dd, 1H, H-7, J = 8.9, 2.7 Hz); 5.52 (s, 2H, CH2-O); 2.26 (s, 3H,
CH3). Anal. C, H, N.
5.1.11. 3-Methyl-8-(2-chloropyridin-4-ylmethyloxy)pyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide (11)
From 9 yellow crystals; TLC eluent: toluene/ethyl acetate 8:2: v/
v; 1H NMR (DMSO-d6) d 8.48 (d, 1H, H-60, J = 5.5 Hz)); 8.38 (d 1H,
H-6, J = 8.9 Hz); 8.14 (s, 1H, H-2); 7.76 (d, 1H, H-9, J = 2.7 Hz);
7.68 (s, 1H, H-30); 7.56 (d, 1H, H-50, J = 5.5 Hz); 7.38 (dd, 1H, H-7,
J = 8.9, 2.7 Hz); 5.50 (s, 2H, CH2-O); 2.26 (s, 3H, CH3). Anal. C, H, N.
5.1.12. 3-Methyl-8-(fur-2-ylmethyloxy)pyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (12)
From 9 yellow crystals; TLC eluent: toluene/ethyl acetate 8:2 v/
v; 1H NMR (DMSO-d6) d 8.35 (d, 1H, H-6, J = 8.9 Hz); 8.15 (s, 1H, H-
2); 7.85 (d, 1H, H-9, J = 2.7 Hz); 7.75 (m, 1H, H-30); 7.30 (dd, 1H, H-
7, J = 8.9, 2.7 Hz); 6.70 (m, 1H, H-50); 6.53 (m, 1H, H-40); 5.40 (s, 2H,
CH2-O); 2.25(s, 3H, CH3). Anal. C, H, N.
5.1.13. 3-(1,2,4-Oxadiazol-3-methyl-5-yl)-8-benzyloxypyrazolo
[5,1-c][1,2,4]benzotriazine5-oxide (13)
From V46 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; 1H NMR (DMSO-d6) d 8.91 (s, 1H, H-2); 8.44 (d, 1H, H-
6, J = 8.9 Hz); d 7.86 (d, 1H, H-9, J = 2.7 Hz); 7.55 (m, 2H, H20 and
H60); 7.44 (m, 4H, H-7, H-30, H-40 and H-50); 5.49 (s, 2H, CH2O);
2.43 (s, 3H, CH3). Anal. C, H, N.
5.1.14. 3-(1,2,4-Oxadiazol-3-methyl-5-yl)-8-(pyridin-4-
ylmethoxy)pyrazolo[5,1-c][1,2,4] benzotriazine5-oxide (14)
From V46 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; 1H NMR (DMSO-d6) d 8.92 (s, 1H, H-2); 8.67 (d, 2H, H-
20 and H-60, J = 5.5 Hz)); 8.47 (d, 1H, H-6, J = 8.9, 2.7 Hz); d 7.87 (d,
1H, H-9, J = 2.7 Hz); 7.61 (d, 2H, H-30 and H-50, J = 5.5 Hz)); 7.52
(dd, 1H, H-7, J = 8.9, 2.7 Hz); 5.61 (s, 2H, CH2O); 2.43 (s, 3H, CH3).
Anal. C, H, N.
5.1.15. 3-(1,2,4-Oxadiazol-3-methyl-5-yl)-8-(thien-2-
ylmethoxy)pyrazolo[5,1-c][1,2,4]benzo triazine5-oxide (15)
From V46 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; 1H NMR (DMSO-d6) d 8.92 (s, 1H, H-2); 8.43 (d, 1H, H-
6, J = 8.9 Hz); d 7.91(d, 1H, H-9, J = 2.7 Hz); 7.63 (d, 1H, H-50,
J = 4.8 Hz); 7.45 (dd, 1H, H-7, J = 8.9, 2.7 Hz); 7.35 (d, 1H, H-30,
J = 3.5 Hz); 7.10 (dt, 1H, H-40, J = 4.8, 3.5 Hz); 5.70 (s, 2H, CH2-O);
2.44 (s, 3H, CH3). Anal. C, H, N.
5.1.16. 3-Carbamoyl-8-benzyloxypyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (16)
From III43 yellow crystals; TLC eluent: toluene/ethyl acetate 8:2
v/v; IR m cm1 3340, 3290, 1684; 1H NMR (DMSO-d6) d 8.56 (s, 1H,
H-2); 8.40 (d 1H, H-6, J = 8.9 Hz); 7.82 (d, 1H, H-9, J = 2.7 Hz); 7.58
(br s, 1H, exch., NH); 7.54 (m, 2H, H-20 and H-60); 7.42 (m, 4H, H-7,
H-30,H-40 and H-50); 7.12 (br s, 1H, exch., NH); 5.47 (s, 2H, CH2O).
Anal. C, H, N.
5.1.17. 3-Carbamoyl-8-(pyridin-4-ylmethoxy)pyrazolo[5,1-c]
[1,2,4]benzotriazine 5-oxide (17)
From III43 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; IR m cm1 3347, 3200, 1685; 1H NMR (DMSO-d6) d
8.63 (d, 2H, H-20 and H-60, J = 5.5 Hz); 8.57 (s, 1H, H-2); 8.43 (d
1H, H-6, J = 8.9 Hz); 7.82 (d, 1H, H-9, J = 2.7 Hz); 7.58 (br s, 1H,
exch., NH); 7.53 (d, 2H, H-30 and H-50, J = 5.5 Hz); 7.47 (dd, 1H,
H-7, J = 8.9, 2.7 Hz); 7.12 (br s, 1H, exch., NH); 5.56 (s, 2H,
CH2-O). Anal. C, H, N.
5.1.18. 3-Carbamoyl-8-(thien-2-ylmethoxy)pyrazolo[5,1-c]
[1,2,4]benzotriazine 5-oxide (18)
From III43 yellow crystals; TLC eluent: toluene/ethyl acetate 8:2
v/v; IR m cm1 3445, 3315, 1670; 1H NMR (DMSO-d6) d 8.58 (s, 1H,
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H-2); 8.39 (d, 1H, H-6, J = 8.9 Hz); 7.87 (d, 1H, H-9, J = 2.7 Hz); 7.63
(d, 1H, H-50, J = 4.8 Hz)); 7.55 (br s, 1H, exch., NH); 7.42 (dd, 1H, H-
7, J = 8.9, 2.7 Hz); 7.39 (d, 1H, H-30, J = 3.5 Hz); 7.09 (m, 2H, exch.,
NH and H-40); 5.56 (s, 2H, CH2-O). Anal. C, H, N.
5.1.19. General procedure for the synthesis of 19–21
To compounds 16–18 (1.9 mmol) in anhydrous toluene
(10 mL) and anhydrous DMF (1 mL) was added dimethylformam-
ide–dimethylacetale (DMF–DMA) to obtain the intermediates
19–21. The reaction mixture was stirred at 100–110 C for 2 h
and after cooling, the residue was filtered and washed with
diethylether.
5.1.20. 3-(N-(Dimethylaminomethylene)carbamoyl)-8-
benzyloxypyrazolo[5,1-c][1,2,4] benzotriazine 5-oxide (19)
From 16 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; IR m cm1 1638; 1H NMR (DMSO-d6) d 8.63 (s, 1H,
H-2); 8.61 (s, 1H, @CH); 8.38 (d 1H, H-6, J = 8.9 Hz); 7.82 (d, 1H,
H-9, J = 2.7 Hz); 7.54 (m, 2H, H-20 and H-60); 7.42 (m, 4H, H-7, H-
30, H-40 and H-50); 5.46 (s, 2H, CH2O); 3.20 (s, 3H, N-CH3); 3.17
(s, 3H, N-CH3). Anal. C, H, N.
5.1.21. 3-(N-(Dimethylaminomethylene)carbamoyl)-8-(pyridin-
4-ylmethoxy)pirazolo[5,1-c][1,2,4]benzotriazine 5-oxide (20)
From 17 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; IR m cm1 1641; 1H NMR (DMSO-d6) d 8.62 (m, 4H,
H-20, H-60; H-2 and @CH); 8.41 (d, 1H, H-6, J = 8.9 Hz); 7.81 (d,
1H, H-9, J = 2.7 Hz); 7.54 (m, 2H, H-30 and H-50); 7.44 (dd, 1H, H-
7, J = 8.9, 2.7 Hz); 5.55 (s, 2H, CH2-O); 3.21 (s, 3H, N-CH3); 3.17
(s, 3H, N-CH3). Anal. C, H, N.
5.1.22. 3-(N-(Dimethylaminomethylene)carbamoyl)-8-(thien-2-
ylmethoxy)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (21)
From 18 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; IR m cm1 1640; 1H NMR (DMSO-d6) d 8.64 (s, 1H,
H-2); 8.60 (s, 1H, @CH); 8.38 (d, 1H, H-6, J = 8.9 Hz); 7.86 (d, 1H,
H-9, J = 2.7 Hz); 7.62 (d, 1H, H-50, J = 4.8 Hz); 7.38 (dd, 1H, H-7,
J = 8.9, 2.7 Hz); 7.34 (d, 1H, H-30, J = 3.5 Hz); 7.09 (dt, 1H, H-40,
J = 4.8, 3.5 Hz); 5.66 (s, 2H, CH2-O); 3.20 (s, 3H, N-CH3); 3.19 (s,
3H, N-CH3). Anal. C, H, N.
5.1.23. General procedure for the synthesis of 22–23
To a suspension of 19 (0.30 mmol) in AcOH (10 mL) was added
hydrazine hydrate (0.30 mmol, 0.05 mL). The reaction was kept at
90–100 C for 2 h. The residue was filtered and recrystallized from
a suitable solvent.
5.1.24. 3-(1,2,4-Triazol-3-yl)-8-benzyloxypyrazolo[5,1-c][1,2,4]
benzotriazine 5-oxide (22)
From 19 yellow crystals; TLC eluent: toluene/ethyl acetate 8:2
v/v; IR m cm1 3230; 1H NMR (DMSO-d6) d 11.7 (br s, 1H, exch.,
NH); 8.66 (s, 1H, H-2); 8.50 (s, 1H, CH triazole); 8.40 (d, 1H, H-6,
J = 8.9 Hz); 7.83 (d, 1H, H-9, J = 2.7 Hz); 7.55(m, 2H, H-20 and H-
60); 7.42 (m, 4H, H-7, H-30, H-40 and H-50); 5.47 (s, 2H, CH2O). Anal.
C, H, N.
5.1.25. 3-(1,2,4-Triazol-3-yl)-8-(pyridin-4-ylmethoxy)
pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (23)
From 20 yellow crystals; TLC eluent: dichloromethane/metha-
nol 10:1 v/v; IR m cm1 3390; 1H NMR (DMSO-d6) d 11.9 (br s,
1H, exch., NH); 8.63 (m, 4H, H-20, H-60; H-2 and CH triazole);
8.43 (d 1H, H-6, J = 8.9 Hz); 7.83 (d, 1H, H-9, J = 2.7 Hz); 7.53 (d,
2H, H-30 and H-50, J = 5.5 Hz); 7.43 (dd, 1H, H-7, J = 8.9, 2.7 Hz);
5.56 (s, 2H, CH2-O). Anal. C, H, N.
5.1.26. 3-(1,2,4-Triazol-1-methyl-5-yl)-8-benzyloxypyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide (24)
To a suspension of 19 (0.30 mmol) in AcOH (10 mL) was added
methylhydrazine (0.05 mL). The reaction was kept at 90–100 C for
2 h. The residue was filtered and recrystallized from a suitable sol-
vent. Yellow crystals; TLC eluent: dichloromethane/methanol 10:1
v/v; 1H NMR (CDCl3) d 8.50 (m, 2H, H-2 and H-6); 8.01 (s, 1H, CH
triazole); 7.88 (d, 1H, H-9, J = 2.7 Hz); 7.46 (m, 5H, phenyl); 7.31
(dd, 1H, H-7, J = 8.9, 2.7 Hz); 5.36 (s, 2H, CH2O); 4.16 (s, 3H, N-
CH3); Crystal data for compound 24 are reported in the Supple-
mentary data; Anal. C, H, N.
5.1.27. 3-(1,2,4-Triazol-1-methyl-3-yl)-8-benzyloxypyrazolo
[5,1-c][1,2,4]benzotriazine 5-oxide (25)
Method a: To a solution of (0.35 mmol) 22 in anhydrous DMF
(15 mL) was added a suspension of 50% NaH (0.76 mmol,
18.2 mg) and an excess of CH3I (0.05 mL).The reaction was kept
at 50–60 C for 18 h. The final solution was evaporated and the
mixture of two isomers (3:1) was purified by recrystallization with
ethanol obtaining compound 25.
Method b: A regioselective alkylation was realized using LiOH
as base and 25 as pure product was obtained. To a solution of 22
(0.035 mmol) in EtOH 96% (15 mL) was added a solution of LiOH
0.25 M (5 mL) and CH3I (0.035 mL). Then the reaction mixture
was refluxed for 20 h and the formed precipitate was filtered and
purified by recrystallization.
Yellow crystals; TLC eluent: dichloromethane/methanol 10:1 v/
v; 1H NMR (CDCl3) d 8.62 (s, 1H, H-2); 8.50 (d, 1H, H-6, J = 8.9 Hz);
8.14 (s, 1H, CH triazole); 7.85 (d, 1H, H-9, J = 2.7 Hz); 7.46 (m, 5H,
phenyl); 7.24 (dd, 1H, H-7, J = 8.9, 2.7 Hz); 5.33 (s, 2H, CH2O); 4.05
(s, 3H, N-CH3). Anal. C, H, N.
5.2. Radioligand binding assay on bovine cerebral cortex
membranes and on GABAA receptor subtypes
[3H]Ro15-1788 (specific activity 70.8 Ci/mmol) was obtained
from NEN Life Sciences products. All the other chemicals, which
were of reagent grade, were obtained from commercial suppliers.
Bovine cerebral cortex membranes were prepared as previously
described.51 The membrane preparations were diluted with
50 mM Tris–citrate buffer, pH 7.4, and used in the binding assay.
Protein concentration was assayed using the method of Lowry.52
[3H]Ro15-1788 binding studies were performed as previously re-
ported. Clonal mammalian cell lines, expressing relatively high lev-
els of GABAA receptor subtypes (a1b2c2, a2b2c2, a5b3c2), were
maintained as previously described in minimum essential medium
Eagle’s with EBSS, supplemented with 10% fetal calf serum, L-gluta-
mine (2 mM), penicillin (100 U/ml), and streptomycin (100 lg/ml)
in a humidified atmosphere of 5% CO2/95% air at 37 C. After re-
moval, the cells were harvested by centrifugation at 500g. The
crude membranes were prepared after homogenization in 10 mM
potassium phosphate, pH 7.4, and differential centrifugation at
48,000 g for 30 min at 4 C. The pellets were washed twice in this
manner before final resuspension in 10 mM potassium phosphate,
pH 7.4, that contained 100 mM potassium chloride [3H]Ro15-1788
binding assays to transfected cell membranes was carried out as
previously described.
In brief, the cell line membranes were incubated in a volume of
500 ll, which contained [3H]Ro15-1788 at a concentration of 1–
2 nM and test compound in the 109–105 M range. Nonspecific
binding was defined by 105 M diazepam. Assays were incubated
to equilibrium for 1 h at 4 C. The compounds were dissolved in
DMSO, the level of which did not exceed 1% and which was main-
tained constant in all tubes. At least six different concentrations of
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each compound were used. The data of n = 5 experiments carried
out in duplicate were analyzed by means of an iterative curve-fit-
ting procedure (program Prism, GraphPad, San Diego, CA), which
provided IC50, Ki, and SEM values for tested compounds, the Ki val-
ues being calculated from the Cheng and Prusoff equation.53
5.3. Pharmacological methods
The experiments were carried out in accordance with the Ani-
mal Protection Law of the Republic of Italy, DL No. 116/1992, based
on the European Communities Council Directive of 24 November
1986 (86/609/EEC). All efforts were made to minimize animal suf-
fering and to reduce the number of animals involved. Male CD-1 al-
bino mice (22–24 g) and male Wistar rats (180–200 g) (Harlan
Italy) were used. Twelve mice and three rats were housed per cage
and fed a standard laboratory diet, with tap water ad libitum for
12h light/dark cycles (lights on at 7 am). The cages were brought
into the experimental room the day before the experiment, for
acclimatization purposes. All experiments were performed be-
tween 10:00 am and 15:00 pm.
5.3.1. Passive-avoidance test
The test was performed according to the step-through method
described by Jarvik.54 The apparatus consisted of a two-compart-
ment acrylic box with a lighted compartment connected to a dark-
ened one by a guillotine door. As soon as the mouse entered the
dark compartment, it received a thermal shock punishment. The
latency times for entering the dark compartment were measured
in the training test and after 24 h in the retention test.
5.3.2. Social learning test
The social learning test was performed according to Dantzer,55
Juvenile male rats (80–100 g) were used as social stimuli for study-
ing adult rats (220–240 g). On the first day of the experiment, a
juvenile rat was introduced into the adult male’s cage and the time
spent in social-investigatory behaviour by the adult male within a
5 min fixed interval was recorded. After 24 h, the same juvenile rat
was placed again into the adult male’s cage and social-investiga-
tory behaviour was recorded during a 5 min interval. On the same
day, the social-investigatory behaviour towards a second unfamil-
iar juvenile rat was also recorded.
5.3.3. Mouse light/dark box test
The apparatus (50 cm long, 20 cm wide, and 20 cm high) con-
sisted of two equal acrylic compartments, one dark and one
light, illuminated by a 60W bulb lamp and separated by a divi-
der with a 10  3-cm opening at floor level. Each mouse was
tested by placing it in the center of the lighted area, facing away
from the dark one, and allowing it to explore the novel environ-
ment for 5 min. The number of transfers from one compartment
to the other and the time spent in the illuminated side were
measured. This test exploited the conflict between the animal’s
tendency to explore a new environment and its fear of bright
light.
5.3.4. Rota-rod test
The integrity of the animals’ motor coordination was assessed
using a rota-rod apparatus (Ugo Basile, Varese, Italy) at a rotating
speed of 24 rpm. The number of falls from the rod in 30 s were
counted 15, 30, 45 and 60 min after drug administration.
5.3.5. Pentylenetetrazole (PTZ)-induced seizure
PTZ (90 mg/kg sc) was injected 30 min after the administration
of drugs. The frequency of the occurrence of clonic generalized
convulsions was noted over a period of 30 min.
5.3.6. Determination of ACh release by cerebral microdialysis
Microdialysis was performed in the rat parietal cortex according
to Giovannini.56 The coordinates used for implantation of the hor-
izontal microdialysis tube (AN 69 membrane, molecular weight cut
off >15 kDa, Dasco, Italy) were AP 0.5 mm and H 2.3 mm from the
bregma.57 One day after surgery, the microdialysis tube was per-
fused at a constant flow rate (2 pl/min) with Ringer solution (NaCl
147, KCl 4.0, CaCl2 1.2 mM) containing 7 pM physostigmine sul-
phate. After a 1 h settling period, the perfusate was collected at
20 min intervals in test tubes containing 5 pl of 0.5 mMHC1 to pre-
vent ACh hydrolysis. The samples were then assayed for ACh con-
tent, either immediately or after freezing. ACh was detected and
quantified by high performance liquid chromatography (HPLC)
with an electrochemical detector, as described by Damsma.58
5.4. Drugs
Diazepam (Valium 10—Roche), flumazenil (Roche), pentylen-
etetrazole (PTZ) (Sigma), scopolamine (Sigma) were used. All drugs
except PTZ were suspended in 1% carboxymethylcellulose sodium
salt and sonicated immediately before use. PTZ was dissolved in
isotonic (NaCl 0.9%) saline solution. Drug concentrations were pre-
pared in such a way that the necessary dose could be administered
in a volume of 10 ml/kg by the po, ip or sc routes.
5.5. Statistical analysis
Results are given as the mean ± SEM. Statistical analysis was
performed by means of ANOVA, followed by Scheffe’s post-hoc
test. Student’s two-tailed t-test was used to verify the significance
between two means. Data were analyzed using a computer pro-
gram (Number Cruncher Statistical System, Version 5.03 9/92).
For percentage values, Chi-Square analysis was used in accordance
with Tallarida and Murray. P <0.05 were considered significant.
5.6. Crystallographic analyses
The data were collected at 150(2)K on Xcalibur3 CCD 4-circle
diffractometer using a graphite monochromator, Mo Ka radiation.
A reference frame was monitored every 50 frames to control the
stability of the crystal and the system revealed no intensity decay.
The data set was corrected for Lorentz, polarization effects, absorp-
tion corrections were performed by the ABSPACK multiscan proce-
dure of the CrysAlis59 data reduction package. The structure was
solved using direct method with SHELXS-97 software, and the
refinement was carried out using the SHELXL-9760 software pack-
age. All non-hydrogen atoms were located from the initial solution
or from subsequent electron density difference maps during the
initial course of the refinement. After locating the non-hydrogen
atoms, the models were refined against F2, first using isotropic
and finally anisotropic thermal displacement parameters. Finally,
the hydrogen atoms were located from the electron density differ-
ence maps and isotropically refined. Programs used in the crystal-
lographic calculations included WinGX61 and ORTEP for graphics.62
Crystal structural data are available from the Cambridge Crystallo-
graphic Data Center CCDC No. 846436
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2013.02.027.
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